GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xbrane Biopharma AB (STU:7XB) » Definitions » E10

Xbrane Biopharma AB (STU:7XB) E10 : €-0.14 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xbrane Biopharma AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xbrane Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2024 was €-0.027. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.14 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-26), Xbrane Biopharma AB's current stock price is €0.0168. Xbrane Biopharma AB's E10 for the quarter that ended in Mar. 2024 was €-0.14. Xbrane Biopharma AB's Shiller PE Ratio of today is .


Xbrane Biopharma AB E10 Historical Data

The historical data trend for Xbrane Biopharma AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xbrane Biopharma AB E10 Chart

Xbrane Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xbrane Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.14

Competitive Comparison of Xbrane Biopharma AB's E10

For the Biotechnology subindustry, Xbrane Biopharma AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xbrane Biopharma AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xbrane Biopharma AB's Shiller PE Ratio falls into.



Xbrane Biopharma AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xbrane Biopharma AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.027/132.2054*132.2054
=-0.027

Current CPI (Mar. 2024) = 132.2054.

Xbrane Biopharma AB Quarterly Data

per share eps CPI Adj_EPS
201312 0.000 100.541 0.000
201409 0.000 100.161 0.000
201412 -0.007 100.225 -0.009
201503 -0.056 99.950 -0.074
201506 -0.069 99.995 -0.091
201509 -0.211 100.228 -0.278
201512 -0.028 100.276 -0.037
201603 -0.017 100.751 -0.022
201606 -0.019 101.019 -0.025
201609 -0.022 101.138 -0.029
201612 -0.020 102.022 -0.026
201703 -0.021 102.022 -0.027
201706 -0.017 102.752 -0.022
201709 -0.017 103.279 -0.022
201712 -0.036 103.793 -0.046
201803 -0.016 103.962 -0.020
201806 -0.057 104.875 -0.072
201809 0.090 105.679 0.113
201812 -0.055 105.912 -0.069
201903 -0.056 105.886 -0.070
201906 -0.060 106.742 -0.074
201909 -0.028 107.214 -0.035
201912 -0.047 107.766 -0.058
202003 -0.035 106.563 -0.043
202006 -0.034 107.498 -0.042
202009 -0.032 107.635 -0.039
202012 -0.033 108.296 -0.040
202103 -0.026 108.360 -0.032
202106 -0.030 108.928 -0.036
202109 -0.020 110.338 -0.024
202112 -0.014 112.486 -0.016
202203 -0.015 114.825 -0.017
202206 -0.014 118.384 -0.016
202209 -0.018 122.296 -0.019
202212 -0.024 126.365 -0.025
202303 -0.009 127.042 -0.009
202306 -0.031 129.407 -0.032
202309 -0.027 130.224 -0.027
202312 -0.055 131.912 -0.055
202403 -0.027 132.205 -0.027

Add all the adjusted EPS together and divide 10 will get our e10.


Xbrane Biopharma AB  (STU:7XB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xbrane Biopharma AB E10 Related Terms

Thank you for viewing the detailed overview of Xbrane Biopharma AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Xbrane Biopharma AB (STU:7XB) Business Description

Traded in Other Exchanges
Address
Retzius vag 8, Solna, SWE, 171 65
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company has a patented protein production platform with up to 12 times greater productivity than standard systems for the production of proteins in E.coli host cells. Xbrane's leading product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. The company's geographical segments include the Middle East, Asia, Europe, and the United States.

Xbrane Biopharma AB (STU:7XB) Headlines

No Headlines